Eintrag weiter verarbeiten
Online-Ressource

Abstract P6-03-08: Androgen receptor (AR): A novel target for radiosensitization and treatment in triple-negative breast cancers (TNBC)

Gespeichert in:

Bibliographische Detailangaben
Zeitschriftentitel: Cancer Research
Personen und Körperschaften: Speers, Corey, Zhao, Shuang G, Liu, Meilan, Evans, Joseph, Alluri, Prasanna, Hayes, Daniel F, Feng, Felix Y, Pierce, Lori J
In: Cancer Research, 75, 2015, 9_Supplement, S. P6-03-08-P6-03-08
Format: E-Article
Sprache: Englisch
veröffentlicht:
American Association for Cancer Research (AACR)
Schlagwörter:
Cancer Research
Oncology
author_facet Speers, Corey
Zhao, Shuang G
Liu, Meilan
Evans, Joseph
Alluri, Prasanna
Hayes, Daniel F
Feng, Felix Y
Pierce, Lori J
Speers, Corey
Zhao, Shuang G
Liu, Meilan
Evans, Joseph
Alluri, Prasanna
Hayes, Daniel F
Feng, Felix Y
Pierce, Lori J
author Speers, Corey
Zhao, Shuang G
Liu, Meilan
Evans, Joseph
Alluri, Prasanna
Hayes, Daniel F
Feng, Felix Y
Pierce, Lori J
spellingShingle Speers, Corey
Zhao, Shuang G
Liu, Meilan
Evans, Joseph
Alluri, Prasanna
Hayes, Daniel F
Feng, Felix Y
Pierce, Lori J
Cancer Research
Abstract P6-03-08: Androgen receptor (AR): A novel target for radiosensitization and treatment in triple-negative breast cancers (TNBC)
Cancer Research
Oncology
author_sort speers, corey
spelling Speers, Corey Zhao, Shuang G Liu, Meilan Evans, Joseph Alluri, Prasanna Hayes, Daniel F Feng, Felix Y Pierce, Lori J 0008-5472 1538-7445 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1538-7445.sabcs14-p6-03-08 <jats:title>Abstract</jats:title> <jats:p>Background: Increased rates of locoregional recurrence have been observed in TNBC despite the use of chemotherapy and radiation (RT). Thus, approaches that result in radiosensitizaton of TNBC are critically needed. We have previously characterized the radiation response of 21 breast cancer cell (BCC) lines using clonogenic survival assays. We now pair this data with high-throughput drug screen data available through cancer cell line encyclopedia studies to identify AR as a top target for radiosensitization and assess AR inhibition as a radiosensitization strategy for TNBC.</jats:p> <jats:p>Methods: Clonogenic survival assays were performed to determine the intrinsic RT sensitivity of 21 BCC lines (0-8 Gy RT). IC50 values were determined for 130 clinically available compounds and correlation coefficients were calculated using IC50 values (for drug sensitivity) and SF-2Gy (for radiation sensitivity). Gene expression was measured using Affymetrix microarrays and protein expression was measured using reverse-phase protein lysate arrays (RPPA) of human tumor samples (n=2,061) and BCC lines (n=51). AR function was assessed using siRNA knockdown or inhibition with MDV3100 (enzalutamide). Kaplan-Meier analysis was performed to determine the clinical impact of AR expression on local control and survival. A Cox proportional hazards model was constructed to identify potential factors of survival, and multivariate analysis was used to determine variables most significantly associated with LRF survival.</jats:p> <jats:p>Results: Our radiosensitizer screen nominated bicalutamide as one of the most effective drugs in treating radioresistant BCC lines (R2= 0.46, p-value &amp;lt;0.001). Recognizing that a subgroup of TNBC includes AR expressing tumors, we interrogated the expression of AR in &amp;gt;2000 human breast tumor samples and found signifi[not]cant heterogeneity in AR expression with an increase in TNBC (35% of tumors) compared to non-TNBC (28% of tumors). This same heterogeneity was also identified in human BCC lines. There was a strong correlation between AR RNA expression and protein expression (R2= 0.72, p &amp;lt;0.0001). Inhibition of AR using both siRNA and MDV3100 induced radiation sensitivity in vitro with an enhancement ratio (ER) of 1.35-1.42 in AR-positive TNBC lines. No such radiosensitization was seen in AR-negative TNBC or ER-positive, AR-negative BCC lines. Radiosensitization was at least partially dependent on impaired dsDNA break repair mediated by DNAPKcs. In vivo assessment of tumor growth inhibition with RT and anti-AR strategies are currently underway. Clinically, analyses of patients with TNBC showed that patients whose tumors had high expression of AR had markedly higher rates of LR after RT than patients with low expression of AR (HR for LR 2.9-3.2, p-value &amp;lt;0.01, 2 independent datasets). There was no difference in LR in TNBC patients not treated with RT when stratified by AR expression status. In multivariate analysis, AR expression was the variable most significantly associated with worse LRF survival after RT with a HR of 3.58 (p-value &amp;lt; 0.01).</jats:p> <jats:p>Conclusion: Our results implicate AR as a mediator of radioresistance in breast cancer and support the rationale for developing clinical strategies to inhibit AR as a novel radiosensitizing target in TNBC.</jats:p> <jats:p>Citation Format: Corey Speers, Shuang G Zhao, Meilan Liu, Joseph Evans, Prasanna Alluri, Daniel F Hayes, Felix Y Feng, Lori J Pierce. Androgen receptor (AR): A novel target for radiosensitization and treatment in triple-negative breast cancers (TNBC) [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P6-03-08.</jats:p> Abstract P6-03-08: Androgen receptor (AR): A novel target for radiosensitization and treatment in triple-negative breast cancers (TNBC) Cancer Research
doi_str_mv 10.1158/1538-7445.sabcs14-p6-03-08
facet_avail Online
Free
finc_class_facet Medizin
format ElectronicArticle
fullrecord blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xNTM4LTc0NDUuc2FiY3MxNC1wNi0wMy0wOA
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xNTM4LTc0NDUuc2FiY3MxNC1wNi0wMy0wOA
institution DE-Gla1
DE-Zi4
DE-15
DE-Rs1
DE-Pl11
DE-105
DE-14
DE-Ch1
DE-L229
DE-D275
DE-Bn3
DE-Brt1
DE-Zwi2
DE-D161
imprint American Association for Cancer Research (AACR), 2015
imprint_str_mv American Association for Cancer Research (AACR), 2015
issn 0008-5472
1538-7445
issn_str_mv 0008-5472
1538-7445
language English
mega_collection American Association for Cancer Research (AACR) (CrossRef)
match_str speers2015abstractp60308androgenreceptoraranoveltargetforradiosensitizationandtreatmentintriplenegativebreastcancerstnbc
publishDateSort 2015
publisher American Association for Cancer Research (AACR)
recordtype ai
record_format ai
series Cancer Research
source_id 49
title Abstract P6-03-08: Androgen receptor (AR): A novel target for radiosensitization and treatment in triple-negative breast cancers (TNBC)
title_unstemmed Abstract P6-03-08: Androgen receptor (AR): A novel target for radiosensitization and treatment in triple-negative breast cancers (TNBC)
title_full Abstract P6-03-08: Androgen receptor (AR): A novel target for radiosensitization and treatment in triple-negative breast cancers (TNBC)
title_fullStr Abstract P6-03-08: Androgen receptor (AR): A novel target for radiosensitization and treatment in triple-negative breast cancers (TNBC)
title_full_unstemmed Abstract P6-03-08: Androgen receptor (AR): A novel target for radiosensitization and treatment in triple-negative breast cancers (TNBC)
title_short Abstract P6-03-08: Androgen receptor (AR): A novel target for radiosensitization and treatment in triple-negative breast cancers (TNBC)
title_sort abstract p6-03-08: androgen receptor (ar): a novel target for radiosensitization and treatment in triple-negative breast cancers (tnbc)
topic Cancer Research
Oncology
url http://dx.doi.org/10.1158/1538-7445.sabcs14-p6-03-08
publishDate 2015
physical P6-03-08-P6-03-08
description <jats:title>Abstract</jats:title> <jats:p>Background: Increased rates of locoregional recurrence have been observed in TNBC despite the use of chemotherapy and radiation (RT). Thus, approaches that result in radiosensitizaton of TNBC are critically needed. We have previously characterized the radiation response of 21 breast cancer cell (BCC) lines using clonogenic survival assays. We now pair this data with high-throughput drug screen data available through cancer cell line encyclopedia studies to identify AR as a top target for radiosensitization and assess AR inhibition as a radiosensitization strategy for TNBC.</jats:p> <jats:p>Methods: Clonogenic survival assays were performed to determine the intrinsic RT sensitivity of 21 BCC lines (0-8 Gy RT). IC50 values were determined for 130 clinically available compounds and correlation coefficients were calculated using IC50 values (for drug sensitivity) and SF-2Gy (for radiation sensitivity). Gene expression was measured using Affymetrix microarrays and protein expression was measured using reverse-phase protein lysate arrays (RPPA) of human tumor samples (n=2,061) and BCC lines (n=51). AR function was assessed using siRNA knockdown or inhibition with MDV3100 (enzalutamide). Kaplan-Meier analysis was performed to determine the clinical impact of AR expression on local control and survival. A Cox proportional hazards model was constructed to identify potential factors of survival, and multivariate analysis was used to determine variables most significantly associated with LRF survival.</jats:p> <jats:p>Results: Our radiosensitizer screen nominated bicalutamide as one of the most effective drugs in treating radioresistant BCC lines (R2= 0.46, p-value &amp;lt;0.001). Recognizing that a subgroup of TNBC includes AR expressing tumors, we interrogated the expression of AR in &amp;gt;2000 human breast tumor samples and found signifi[not]cant heterogeneity in AR expression with an increase in TNBC (35% of tumors) compared to non-TNBC (28% of tumors). This same heterogeneity was also identified in human BCC lines. There was a strong correlation between AR RNA expression and protein expression (R2= 0.72, p &amp;lt;0.0001). Inhibition of AR using both siRNA and MDV3100 induced radiation sensitivity in vitro with an enhancement ratio (ER) of 1.35-1.42 in AR-positive TNBC lines. No such radiosensitization was seen in AR-negative TNBC or ER-positive, AR-negative BCC lines. Radiosensitization was at least partially dependent on impaired dsDNA break repair mediated by DNAPKcs. In vivo assessment of tumor growth inhibition with RT and anti-AR strategies are currently underway. Clinically, analyses of patients with TNBC showed that patients whose tumors had high expression of AR had markedly higher rates of LR after RT than patients with low expression of AR (HR for LR 2.9-3.2, p-value &amp;lt;0.01, 2 independent datasets). There was no difference in LR in TNBC patients not treated with RT when stratified by AR expression status. In multivariate analysis, AR expression was the variable most significantly associated with worse LRF survival after RT with a HR of 3.58 (p-value &amp;lt; 0.01).</jats:p> <jats:p>Conclusion: Our results implicate AR as a mediator of radioresistance in breast cancer and support the rationale for developing clinical strategies to inhibit AR as a novel radiosensitizing target in TNBC.</jats:p> <jats:p>Citation Format: Corey Speers, Shuang G Zhao, Meilan Liu, Joseph Evans, Prasanna Alluri, Daniel F Hayes, Felix Y Feng, Lori J Pierce. Androgen receptor (AR): A novel target for radiosensitization and treatment in triple-negative breast cancers (TNBC) [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P6-03-08.</jats:p>
container_issue 9_Supplement
container_start_page 0
container_title Cancer Research
container_volume 75
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
_version_ 1792327990516908035
geogr_code not assigned
last_indexed 2024-03-01T12:46:10.813Z
geogr_code_person not assigned
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Abstract+P6-03-08%3A+Androgen+receptor+%28AR%29%3A+A+novel+target+for+radiosensitization+and+treatment+in+triple-negative+breast+cancers+%28TNBC%29&rft.date=2015-05-01&genre=article&issn=1538-7445&volume=75&issue=9_Supplement&pages=P6-03-08-P6-03-08&jtitle=Cancer+Research&atitle=Abstract+P6-03-08%3A+Androgen+receptor+%28AR%29%3A+A+novel+target+for+radiosensitization+and+treatment+in+triple-negative+breast+cancers+%28TNBC%29&aulast=Pierce&aufirst=Lori+J&rft_id=info%3Adoi%2F10.1158%2F1538-7445.sabcs14-p6-03-08&rft.language%5B0%5D=eng
SOLR
_version_ 1792327990516908035
author Speers, Corey, Zhao, Shuang G, Liu, Meilan, Evans, Joseph, Alluri, Prasanna, Hayes, Daniel F, Feng, Felix Y, Pierce, Lori J
author_facet Speers, Corey, Zhao, Shuang G, Liu, Meilan, Evans, Joseph, Alluri, Prasanna, Hayes, Daniel F, Feng, Felix Y, Pierce, Lori J, Speers, Corey, Zhao, Shuang G, Liu, Meilan, Evans, Joseph, Alluri, Prasanna, Hayes, Daniel F, Feng, Felix Y, Pierce, Lori J
author_sort speers, corey
container_issue 9_Supplement
container_start_page 0
container_title Cancer Research
container_volume 75
description <jats:title>Abstract</jats:title> <jats:p>Background: Increased rates of locoregional recurrence have been observed in TNBC despite the use of chemotherapy and radiation (RT). Thus, approaches that result in radiosensitizaton of TNBC are critically needed. We have previously characterized the radiation response of 21 breast cancer cell (BCC) lines using clonogenic survival assays. We now pair this data with high-throughput drug screen data available through cancer cell line encyclopedia studies to identify AR as a top target for radiosensitization and assess AR inhibition as a radiosensitization strategy for TNBC.</jats:p> <jats:p>Methods: Clonogenic survival assays were performed to determine the intrinsic RT sensitivity of 21 BCC lines (0-8 Gy RT). IC50 values were determined for 130 clinically available compounds and correlation coefficients were calculated using IC50 values (for drug sensitivity) and SF-2Gy (for radiation sensitivity). Gene expression was measured using Affymetrix microarrays and protein expression was measured using reverse-phase protein lysate arrays (RPPA) of human tumor samples (n=2,061) and BCC lines (n=51). AR function was assessed using siRNA knockdown or inhibition with MDV3100 (enzalutamide). Kaplan-Meier analysis was performed to determine the clinical impact of AR expression on local control and survival. A Cox proportional hazards model was constructed to identify potential factors of survival, and multivariate analysis was used to determine variables most significantly associated with LRF survival.</jats:p> <jats:p>Results: Our radiosensitizer screen nominated bicalutamide as one of the most effective drugs in treating radioresistant BCC lines (R2= 0.46, p-value &amp;lt;0.001). Recognizing that a subgroup of TNBC includes AR expressing tumors, we interrogated the expression of AR in &amp;gt;2000 human breast tumor samples and found signifi[not]cant heterogeneity in AR expression with an increase in TNBC (35% of tumors) compared to non-TNBC (28% of tumors). This same heterogeneity was also identified in human BCC lines. There was a strong correlation between AR RNA expression and protein expression (R2= 0.72, p &amp;lt;0.0001). Inhibition of AR using both siRNA and MDV3100 induced radiation sensitivity in vitro with an enhancement ratio (ER) of 1.35-1.42 in AR-positive TNBC lines. No such radiosensitization was seen in AR-negative TNBC or ER-positive, AR-negative BCC lines. Radiosensitization was at least partially dependent on impaired dsDNA break repair mediated by DNAPKcs. In vivo assessment of tumor growth inhibition with RT and anti-AR strategies are currently underway. Clinically, analyses of patients with TNBC showed that patients whose tumors had high expression of AR had markedly higher rates of LR after RT than patients with low expression of AR (HR for LR 2.9-3.2, p-value &amp;lt;0.01, 2 independent datasets). There was no difference in LR in TNBC patients not treated with RT when stratified by AR expression status. In multivariate analysis, AR expression was the variable most significantly associated with worse LRF survival after RT with a HR of 3.58 (p-value &amp;lt; 0.01).</jats:p> <jats:p>Conclusion: Our results implicate AR as a mediator of radioresistance in breast cancer and support the rationale for developing clinical strategies to inhibit AR as a novel radiosensitizing target in TNBC.</jats:p> <jats:p>Citation Format: Corey Speers, Shuang G Zhao, Meilan Liu, Joseph Evans, Prasanna Alluri, Daniel F Hayes, Felix Y Feng, Lori J Pierce. Androgen receptor (AR): A novel target for radiosensitization and treatment in triple-negative breast cancers (TNBC) [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P6-03-08.</jats:p>
doi_str_mv 10.1158/1538-7445.sabcs14-p6-03-08
facet_avail Online, Free
finc_class_facet Medizin
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xNTM4LTc0NDUuc2FiY3MxNC1wNi0wMy0wOA
imprint American Association for Cancer Research (AACR), 2015
imprint_str_mv American Association for Cancer Research (AACR), 2015
institution DE-Gla1, DE-Zi4, DE-15, DE-Rs1, DE-Pl11, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161
issn 0008-5472, 1538-7445
issn_str_mv 0008-5472, 1538-7445
language English
last_indexed 2024-03-01T12:46:10.813Z
match_str speers2015abstractp60308androgenreceptoraranoveltargetforradiosensitizationandtreatmentintriplenegativebreastcancerstnbc
mega_collection American Association for Cancer Research (AACR) (CrossRef)
physical P6-03-08-P6-03-08
publishDate 2015
publishDateSort 2015
publisher American Association for Cancer Research (AACR)
record_format ai
recordtype ai
series Cancer Research
source_id 49
spelling Speers, Corey Zhao, Shuang G Liu, Meilan Evans, Joseph Alluri, Prasanna Hayes, Daniel F Feng, Felix Y Pierce, Lori J 0008-5472 1538-7445 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1538-7445.sabcs14-p6-03-08 <jats:title>Abstract</jats:title> <jats:p>Background: Increased rates of locoregional recurrence have been observed in TNBC despite the use of chemotherapy and radiation (RT). Thus, approaches that result in radiosensitizaton of TNBC are critically needed. We have previously characterized the radiation response of 21 breast cancer cell (BCC) lines using clonogenic survival assays. We now pair this data with high-throughput drug screen data available through cancer cell line encyclopedia studies to identify AR as a top target for radiosensitization and assess AR inhibition as a radiosensitization strategy for TNBC.</jats:p> <jats:p>Methods: Clonogenic survival assays were performed to determine the intrinsic RT sensitivity of 21 BCC lines (0-8 Gy RT). IC50 values were determined for 130 clinically available compounds and correlation coefficients were calculated using IC50 values (for drug sensitivity) and SF-2Gy (for radiation sensitivity). Gene expression was measured using Affymetrix microarrays and protein expression was measured using reverse-phase protein lysate arrays (RPPA) of human tumor samples (n=2,061) and BCC lines (n=51). AR function was assessed using siRNA knockdown or inhibition with MDV3100 (enzalutamide). Kaplan-Meier analysis was performed to determine the clinical impact of AR expression on local control and survival. A Cox proportional hazards model was constructed to identify potential factors of survival, and multivariate analysis was used to determine variables most significantly associated with LRF survival.</jats:p> <jats:p>Results: Our radiosensitizer screen nominated bicalutamide as one of the most effective drugs in treating radioresistant BCC lines (R2= 0.46, p-value &amp;lt;0.001). Recognizing that a subgroup of TNBC includes AR expressing tumors, we interrogated the expression of AR in &amp;gt;2000 human breast tumor samples and found signifi[not]cant heterogeneity in AR expression with an increase in TNBC (35% of tumors) compared to non-TNBC (28% of tumors). This same heterogeneity was also identified in human BCC lines. There was a strong correlation between AR RNA expression and protein expression (R2= 0.72, p &amp;lt;0.0001). Inhibition of AR using both siRNA and MDV3100 induced radiation sensitivity in vitro with an enhancement ratio (ER) of 1.35-1.42 in AR-positive TNBC lines. No such radiosensitization was seen in AR-negative TNBC or ER-positive, AR-negative BCC lines. Radiosensitization was at least partially dependent on impaired dsDNA break repair mediated by DNAPKcs. In vivo assessment of tumor growth inhibition with RT and anti-AR strategies are currently underway. Clinically, analyses of patients with TNBC showed that patients whose tumors had high expression of AR had markedly higher rates of LR after RT than patients with low expression of AR (HR for LR 2.9-3.2, p-value &amp;lt;0.01, 2 independent datasets). There was no difference in LR in TNBC patients not treated with RT when stratified by AR expression status. In multivariate analysis, AR expression was the variable most significantly associated with worse LRF survival after RT with a HR of 3.58 (p-value &amp;lt; 0.01).</jats:p> <jats:p>Conclusion: Our results implicate AR as a mediator of radioresistance in breast cancer and support the rationale for developing clinical strategies to inhibit AR as a novel radiosensitizing target in TNBC.</jats:p> <jats:p>Citation Format: Corey Speers, Shuang G Zhao, Meilan Liu, Joseph Evans, Prasanna Alluri, Daniel F Hayes, Felix Y Feng, Lori J Pierce. Androgen receptor (AR): A novel target for radiosensitization and treatment in triple-negative breast cancers (TNBC) [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P6-03-08.</jats:p> Abstract P6-03-08: Androgen receptor (AR): A novel target for radiosensitization and treatment in triple-negative breast cancers (TNBC) Cancer Research
spellingShingle Speers, Corey, Zhao, Shuang G, Liu, Meilan, Evans, Joseph, Alluri, Prasanna, Hayes, Daniel F, Feng, Felix Y, Pierce, Lori J, Cancer Research, Abstract P6-03-08: Androgen receptor (AR): A novel target for radiosensitization and treatment in triple-negative breast cancers (TNBC), Cancer Research, Oncology
title Abstract P6-03-08: Androgen receptor (AR): A novel target for radiosensitization and treatment in triple-negative breast cancers (TNBC)
title_full Abstract P6-03-08: Androgen receptor (AR): A novel target for radiosensitization and treatment in triple-negative breast cancers (TNBC)
title_fullStr Abstract P6-03-08: Androgen receptor (AR): A novel target for radiosensitization and treatment in triple-negative breast cancers (TNBC)
title_full_unstemmed Abstract P6-03-08: Androgen receptor (AR): A novel target for radiosensitization and treatment in triple-negative breast cancers (TNBC)
title_short Abstract P6-03-08: Androgen receptor (AR): A novel target for radiosensitization and treatment in triple-negative breast cancers (TNBC)
title_sort abstract p6-03-08: androgen receptor (ar): a novel target for radiosensitization and treatment in triple-negative breast cancers (tnbc)
title_unstemmed Abstract P6-03-08: Androgen receptor (AR): A novel target for radiosensitization and treatment in triple-negative breast cancers (TNBC)
topic Cancer Research, Oncology
url http://dx.doi.org/10.1158/1538-7445.sabcs14-p6-03-08